加科思(01167.HK)KRAS G12C抑制剂获批上市 将收5,000万元里程碑付款

阿斯达克财经
22 May

加科思(01167.HK) 公布,根据国家药品监督管理局官方网站信息,公司自主研发的KRAS G12C抑制剂艾瑞凯(通用名:戈来雷塞)正式获批上市。适应症为至少经历过一种系统性治疗的KRAS G12C突变的非小细胞肺癌。
此次获批触发里程碑付款条件,加科思将收到来自合作伙伴上海艾力斯医药科技股份有限公司(688578.SH) 5,000万元里程碑付款。(sl/u)(港股报价延迟最少十五分钟。) (A股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10